You are here

Generic Version of Phenergan Approved

SOUTH PLAINFIELD, N.J., July 1 /PRNewswire-FirstCall/ -- ABLE LABORATORIES, INC. , today announced that it has received Food and Drug Administration approval for its Abbreviated New Drug Applications for Promethazine Hydrochloride Tablets, USP 12,5mg, 25mg and 50mg, which are therapeutically equivalent to Phenergan® Tablets 12.5mg, 25mg and 50mg of Wyeth Ayerst Laboratories. The total sales for Able's newly approved drugs (used in the treatment of nausea and vomiting associated with certain types of anesthesia and surgery), is estimated to be approximately $70 million according to recent market data.

Able is the first company to offer AB-Rated generic version of Promethazine Hydrochloride Tablets, USP 12.5mg and the only company to market AB-Rated generic version of all three tablet products. This approval, along with Able's Promethazine Hydrochloride suppository products, represents the expansion of Able's line of Promethazine-based products.

Able Laboratories is a developer and manufacturer of generic pharmaceuticals. Further information on Able may be found on the Company's web site,

Recent Headlines

First New Medication for Seizure Clusters in More Than Two Decades
Novel, Low-cost Device Highly Accurate at Screening Newborn Jaundice
Mode Delivers Antivirals Safely, Cheaply to Remote Regions
First Devices Cleared for Diagnostic Testing Via Throat, Rectum Specimens
Averts Disease Worsening, Reduces Potential for Blindness
Risk May Remain for 6 Months After Treatment
FDA Removes Boxed Warning With Drug’s Fifth Approval
Overeager Use of Recommendations Creates Problems
Artificial Intelligence Enables Platform to Detect Amyloid PET Status